These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 20688287)
1. Non-Hodgkin's lymphoma in patients with human immunodeficiency virus infection in Taiwan. Yang CJ; Chen MY; Hsieh SM; Sheng WH; Sun HY; Hung CC; Chang SC J Microbiol Immunol Infect; 2010 Aug; 43(4):278-84. PubMed ID: 20688287 [TBL] [Abstract][Full Text] [Related]
2. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. Robotin MC; Law MG; Milliken S; Goldstein D; Garsia RJ; Dolan GM; Kaldor JM; Grulich AE HIV Med; 2004 Sep; 5(5):377-84. PubMed ID: 15369514 [TBL] [Abstract][Full Text] [Related]
3. Kaposi's sarcoma in patients with human immunodeficiency virus infection in Taiwan. Lin CY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Lo YC; Hung CC; Chang SC J Microbiol Immunol Infect; 2009 Jun; 42(3):227-33. PubMed ID: 19812856 [TBL] [Abstract][Full Text] [Related]
4. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003]. Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104 [TBL] [Abstract][Full Text] [Related]
5. AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico. Cornejo-Juárez P; Volkow-Fernández P; Avilés-Salas A; Calderón-Flores E Rev Invest Clin; 2008; 60(5):375-81. PubMed ID: 19227434 [TBL] [Abstract][Full Text] [Related]
6. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382 [TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S; AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233 [TBL] [Abstract][Full Text] [Related]
8. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F; Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870 [TBL] [Abstract][Full Text] [Related]
9. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Vaccher E; Spina M; Talamini R; Zanetti M; di Gennaro G; Nasti G; Tavio M; Bernardi D; Simonelli C; Tirelli U Clin Infect Dis; 2003 Dec; 37(11):1556-64. PubMed ID: 14614680 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675 [TBL] [Abstract][Full Text] [Related]
11. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic. Ives NJ; Gazzard BG; Easterbrook PJ J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320 [TBL] [Abstract][Full Text] [Related]
12. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta. Gingues S; Gill MJ HIV Med; 2006 Sep; 7(6):369-77. PubMed ID: 16903981 [TBL] [Abstract][Full Text] [Related]
13. Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection. Spina M; Carbone A; Vaccher E; Gloghini A; Talamini R; Cinelli R; Martellotta F; Tirelli U Clin Infect Dis; 2004 Jan; 38(1):142-4. PubMed ID: 14679461 [TBL] [Abstract][Full Text] [Related]
14. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance. Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981 [TBL] [Abstract][Full Text] [Related]
15. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Thiessard F; Morlat P; Marimoutou C; Labouyrie E; Ragnaud JM; Pellegrin JL; Dupon M; Dabis F Cancer; 2000 Apr; 88(7):1696-702. PubMed ID: 10738229 [TBL] [Abstract][Full Text] [Related]
16. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy. Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865 [TBL] [Abstract][Full Text] [Related]
17. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469 [TBL] [Abstract][Full Text] [Related]
18. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Diamond C; Taylor TH; Aboumrad T; Anton-Culver H Cancer; 2006 Jan; 106(1):128-35. PubMed ID: 16329140 [TBL] [Abstract][Full Text] [Related]
19. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy. Wong KH; Chan KC; Lee SS Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819 [TBL] [Abstract][Full Text] [Related]
20. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy inl the post highly active antiretroviral therapy era? Clayton A; Mughal T Hematol Oncol; 2004 Sep; 22(3):111-20. PubMed ID: 15991221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]